Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) major shareholder Mubadala Investment Co Pjsc bought 24,526 shares of the business's stock in a transaction that occurred on Wednesday, January 25th. The shares were purchased at an average price of $7.88 per share, for a total transaction of $193,264.88. Following the completion of the purchase, the insider now directly owns 12,346,258 shares of the company's stock, valued at approximately $97,288,513.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Mubadala Investment Co Pjsc also recently made the following trade(s):
Get
Recursion Pharmaceuticals alerts:
- On Monday, January 9th, Mubadala Investment Co Pjsc acquired 76,046 shares of Recursion Pharmaceuticals stock. The stock was purchased at an average cost of $7.64 per share, for a total transaction of $580,991.44.
- On Thursday, January 5th, Mubadala Investment Co Pjsc acquired 80,035 shares of Recursion Pharmaceuticals stock. The shares were purchased at an average cost of $7.38 per share, with a total value of $590,658.30.
- On Tuesday, January 3rd, Mubadala Investment Co Pjsc bought 141,646 shares of Recursion Pharmaceuticals stock. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $1,062,345.00.
Recursion Pharmaceuticals Price Performance
NASDAQ RXRX opened at $8.54 on Friday. The company has a fifty day moving average of $8.41 and a two-hundred day moving average of $9.76. The company has a market capitalization of $1.62 billion, a PE ratio of -5.93 and a beta of -0.47. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.92 and a 1 year high of $14.18.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01. The firm had revenue of $13.16 million during the quarter, compared to analysts' expectations of $6.43 million. Recursion Pharmaceuticals had a negative return on equity of 53.04% and a negative net
margin of 860.34%. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.37 earnings per share for the current year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. boosted its stake in Recursion Pharmaceuticals by 23.2% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 7,319 shares of the company's stock worth $77,000 after purchasing an additional 1,378 shares during the period. Arizona State Retirement System boosted its stake in shares of Recursion Pharmaceuticals by 20.3% during the second quarter. Arizona State Retirement System now owns 12,969 shares of the company's stock worth $106,000 after buying an additional 2,188 shares during the period. Baldwin Brothers LLC MA grew its holdings in shares of Recursion Pharmaceuticals by 100.0% during the third quarter. Baldwin Brothers LLC MA now owns 5,502 shares of the company's stock worth $59,000 after buying an additional 2,751 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in Recursion Pharmaceuticals by 6.8% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 51,453 shares of the company's stock valued at $419,000 after acquiring an additional 3,259 shares during the period. Finally, Albion Financial Group UT raised its stake in Recursion Pharmaceuticals by 3,385.0% during the 3rd quarter. Albion Financial Group UT now owns 4,182 shares of the company's stock valued at $44,000 after acquiring an additional 4,062 shares during the last quarter. 63.62% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on RXRX shares. SVB Leerink lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Monday, January 23rd. The Goldman Sachs Group upped their price target on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the company a "neutral" rating in a report on Wednesday, November 9th.
About Recursion Pharmaceuticals
(Get Rating)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
Featured Stories
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
